Healthcare provider profile · identity verified

Ravindra Mullapudi, MD

Family Practice · HUBER HEIGHTS, OH · NPI 1811943822

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	569	194
Levothyroxine Sodium	Levothyroxine Sodium	338	115
Omeprazole	Omeprazole	324	110
Lisinopril	Lisinopril	285	94
Metformin Hcl	Metformin Hcl	270	89
Amlodipine Besylate	Amlodipine Besylate	227	92
Gabapentin	Gabapentin	210	61
Rosuvastatin Calcium	Rosuvastatin Calcium	200	43
Hydrochlorothiazide	Hydrochlorothiazide	187	71
Losartan Potassium	Losartan Potassium	181	58
Albuterol Sulfate Hfa	Albuterol Sulfate	176	66
Pravastatin Sodium	Pravastatin Sodium	156	51
Simvastatin	Simvastatin	127	47
Tamsulosin Hcl	Tamsulosin Hcl	125	44
Metoprolol Succinate	Metoprolol Succinate	120	42
Trazodone Hcl	Trazodone Hcl	113	22
Metoprolol Tartrate	Metoprolol Tartrate	109	39
Glipizide	Glipizide	101	31
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	98	34
Januvia	Sitagliptin Phosphate	93	20
Citalopram Hbr	Citalopram Hydrobromide	84	25
Glimepiride	Glimepiride	82	25
Potassium Chloride	Potassium Chloride	81	25
Furosemide	Furosemide	79	35
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	77	29
Alendronate Sodium	Alendronate Sodium	75	22
Metformin Hcl Er	Metformin Hcl	71	18
Isosorbide Mononitrate Er	Isosorbide Mononitrate	68	suppressed
Montelukast Sodium	Montelukast Sodium	68	27
Pantoprazole Sodium	Pantoprazole Sodium	68	28
Fluticasone Propionate	Fluticasone Propionate	64	33
Meloxicam	Meloxicam	64	28
Alprazolam	Alprazolam	63	11
Jardiance	Empagliflozin	62	16
Prednisone	Prednisone	61	55
Paroxetine Hcl	Paroxetine Hcl	56	21
Fenofibrate	Fenofibrate	55	15
Ibuprofen	Ibuprofen	55	32
Clopidogrel	Clopidogrel Bisulfate	53	21
Esomeprazole Magnesium	Esomeprazole Magnesium	50	suppressed
Ezetimibe	Ezetimibe	46	13
Risperidone	Risperidone	46	suppressed
Lorazepam	Lorazepam	44	13
Fenofibrate	Fenofibrate Nanocrystallized	43	14
Meclizine Hcl	Meclizine Hcl	43	23
Amoxicillin	Amoxicillin	41	38
Sertraline Hcl	Sertraline Hcl	41	13
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	39	25
Donepezil Hcl	Donepezil Hcl	38	12
Synthroid	Levothyroxine Sodium	38	15
Allopurinol	Allopurinol	37	13
Lovastatin	Lovastatin	36	suppressed
Ozempic	Semaglutide	36	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	35	13
Bisoprolol-Hydrochlorothiazide	Bisoprolol/Hydrochlorothiazide	34	12
Atenolol	Atenolol	32	13
Eliquis	Apixaban	32	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	29	suppressed
Carvedilol	Carvedilol	28	11
Methocarbamol	Methocarbamol	28	28
Oseltamivir Phosphate	Oseltamivir Phosphate	28	26
Spironolactone	Spironolactone	27	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	26	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	26	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	25	suppressed
Klor-Con M20	Potassium Chloride	25	suppressed
Chlorthalidone	Chlorthalidone	24	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	24	21
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	24	suppressed
Famotidine	Famotidine	24	suppressed
Azelastine Hcl	Azelastine Hcl	23	13
Buspirone Hcl	Buspirone Hcl	23	suppressed
Duloxetine Hcl	Duloxetine Hcl	23	suppressed
Azithromycin	Azithromycin	22	19
Cephalexin	Cephalexin	22	21
Clonazepam	Clonazepam	21	suppressed
Farxiga	Dapagliflozin Propanediol	21	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	20	suppressed
Betamethasone Diprop Augmented	Betamethasone/Propylene Glyc	19	suppressed
Gemfibrozil	Gemfibrozil	19	suppressed
Nifedipine Er	Nifedipine	19	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	19	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	18	suppressed
Janumet Xr	Sitagliptin Phos/Metformin Hcl	18	suppressed
Mirtazapine	Mirtazapine	18	suppressed
Verapamil Er	Verapamil Hcl	18	suppressed
Diclofenac Sodium	Diclofenac Sodium	17	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	17	suppressed
Fluvoxamine Maleate	Fluvoxamine Maleate	17	suppressed
Glipizide Er	Glipizide	17	suppressed
Hydralazine Hcl	Hydralazine Hcl	17	suppressed
Tizanidine Hcl	Tizanidine Hcl	17	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	16	suppressed
Finasteride	Finasteride	16	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	16	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	15	suppressed
Tramadol Hcl	Tramadol Hcl	15	11
Valsartan	Valsartan	15	suppressed
Ipratropium Bromide	Ipratropium Bromide	14	suppressed
Livalo	Pitavastatin Calcium	14	suppressed
Methylprednisolone	Methylprednisolone	14	13
Naproxen	Naproxen	14	13
Tradjenta	Linagliptin	14	suppressed
Penicillin V Potassium	Penicillin V Potassium	13	suppressed
Ropinirole Hcl	Ropinirole Hcl	13	suppressed
Xarelto	Rivaroxaban	13	suppressed
Baclofen	Baclofen	12	suppressed
Bydureon Bcise	Exenatide Microspheres	12	suppressed
Clonidine Hcl	Clonidine Hcl	12	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	12	suppressed
Primidone	Primidone	12	suppressed
Bupropion Xl	Bupropion Hcl	11	suppressed
Celecoxib	Celecoxib	11	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	11	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error